On this page
Hydrocodone Bitartrate and Acetaminophen
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Acetaminophen | 300 mg/1 | 313782 | View |
| Acetaminophen | 325 mg/1 | 313782 | View |
| Hydrocodone Bitartrate | 10 mg/1 | 856999 | View |
| Hydrocodone Bitartrate | 2.5 mg/1 | 856999 | View |
| Hydrocodone Bitartrate | 5 mg/1 | 856999 | View |
| Hydrocodone Bitartrate | 7.5 mg/1 | 856999 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Opioid Agonist [EPC] | EPC | All 109 members |
| Opioid Agonists [MoA] | MoA | All 35 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 202214-001 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | TABLET | ACETAMINOPHEN; HYDROCODONE BITARTRATE | Prescription | AA | ||
| 202214-002 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | TABLET | ACETAMINOPHEN; HYDROCODONE BITARTRATE | Prescription | AA | ||
| 202214-003 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | TABLET | ACETAMINOPHEN; HYDROCODONE BITARTRATE | Prescription | AA | ||
| 202214-004 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | TABLET | ACETAMINOPHEN; HYDROCODONE BITARTRATE | Prescription | AA | ||
| 202214-005 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | TABLET | ACETAMINOPHEN; HYDROCODONE BITARTRATE | Prescription | AA | ||
| 202214-006 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | TABLET | ACETAMINOPHEN; HYDROCODONE BITARTRATE | Prescription | AA |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — no known or suspected bioequivalence problems (conventional dosage forms)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 27 | REMS | Approved | June 18, 2026 | — |
| Supplement | 26 | Labeling | Approved | December 22, 2025 | Standard |
| Supplement | 20 | Labeling | Approved | December 22, 2025 | Standard |
| Supplement | 21 | REMS | Approved | October 31, 2024 | — |
| Supplement | 18 | Labeling | Approved | December 15, 2023 | Standard |
| Supplement | 17 | Labeling | Approved | December 15, 2023 | Standard |
| Supplement | 14 | Labeling | Approved | March 4, 2021 | Standard |
| Supplement | 10 | Labeling | Approved | October 11, 2019 | Standard |
| Supplement | 9 | Labeling | Approved | September 21, 2018 | Standard |
| Supplement | 8 | REMS | Approved | September 18, 2018 | — |
| Supplement | 7 | Labeling | Approved | September 12, 2018 | Standard |
| Supplement | 5 | Labeling | Approved | September 12, 2018 | Standard |
| Supplement | 4 | Labeling | Approved | December 16, 2016 | Standard |
| Supplement | 3 | Labeling | Approved | December 16, 2016 | Standard |
| Supplement | 2 | Manufacturing (CMC) | Approved | March 15, 2016 | Unknown |
| Supplement | 1 | Labeling | Approved | October 18, 2013 | Standard |
| Original application | 1 | Approved | March 27, 2013 | — |
Review documents
- 0 · Original application · November 3, 2023
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260608). This is the manufacturer's labelling text, not a summary and not advice.
Boxed Warning
openFDA Drug LabelingWARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; HEPATOTOXICITY; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Hydrocodone Bitartrate and Acetaminophen Tablet exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing Hydrocodone Bitartrate and Acetaminophen Tablets, and monitor all patients regularly for the development of these behaviors or conditions [see WARNINGS ]. Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS): To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a REMS for these products [see Warnings ]. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to • complete a REMS-compliant education program, • counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products, • emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist, and • consider other tools to improve patient, household, and community safety. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of Hydrocodone Bitartrate and Acetaminophen Tablets. Monitor for respiratory depression, especially during initiation of Hydrocodone Bitartrate and Acetaminophen Tablets or following a dose increase [see WARNINGS ]. Accidental Ingestion Accidental ingestion of even one dose of Hydrocodone Bitartrate and Acetaminophen Tablets especially by children, can result in a fatal overdose of Hydrocodone Bitartrate and Acetaminophen Tablets [see WARNINGS ]. Neonatal Opioid Withdrawal Syndrome Prolonged use of Hydrocodone Bitartrate and Acetaminophen Tablets during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see WARNINGS ]. Cytochrome P450 3A4 Interaction The concomitant use of Hydrocodone Bitartrate and Acetaminophen Tablets with all cytochrome P450 3A4 inhibitors may result in an increase in Hydrocodone Bitartrate and Acetaminophen Tablets plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in Hydrocodone Bitartrate and Acetaminophen Tablets plasma concentrations. Monitor patients receiving Hydrocodone Bitartrate and Acetaminophen Tablets and any Cytochrome P450 3A4 inhibitor or inducer for signs of respiratory depression or sedation [see CLINICAL PHARMACOLOGY , WARNINGS , PRECAUTIONS; Drug Interactions ]. Hepatotoxicity Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen containing product.[see WARNINGS, OVERDOSAGE ]. Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, …
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Hydrocodone Bitartrate and Acetaminophen Tablets, USP are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see WARNINGS ] , reserve hydrocodone bitartrate and acetaminophen tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia Hydrocodone bitartrate and acetaminophen tablets should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Important Dosage and Administration Instructions Hydrocodone Bitartrate and Acetaminophen Tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks. Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals [see WARNINGS ]. Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of Hydrocodone Bitartrate and Acetaminophen Tablets for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks. Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an opioid analgesic. Clinical guidelines on opioid prescribing for some acute pain conditions are available. There is variability in the opioid analgesic dose and duration needed to adequately manage pain due both to the cause of pain and to individual patient factors. Initiate the dosing regimen for each patient individually, taking into account the patient’s underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse [see WARNINGS ]. Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with Hydrocodone Bitartrate and Acetaminophen Tablets. Consider this risk when selecting an initial dose and when making dose adjustments [see WARNINGS ]. Patient Access to an Opioid Overdose Reversal Agent for the Emergency Treatment of Opioid Overdose Inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene). Discuss the importance of having access to an opioid overdose reversal agent, especially if the patient has risk factors for overdose (e.g., concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose) or if there are household members (including children) or other close contacts at risk for accidental ingestion or opioid overdose. The presence of risk factors for overdose should not prevent the management of pain in any patient [see WARNINGS; Addiction, Abuse, and Misuse ; Life-Threatening Respiratory Depression ; Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants ]. Discuss the options for obtaining an opioid overdose reversal agent (e.g., prescription, over-the-counter, or as part of a community-based program). There are important differences among the opioid overdose reversal agents, such as route of administration, product strength, approved patient age range, and pharmacokinetics. Be familiar with these differences, as outlined in the approved labeling for those products, prior to recommending or prescribing such an agent. Initial Dosage Use of Hydrocodone Bitartrate and Acetaminophen Tablets as the First Opioid Analgesic 7.5 mg/325 mg Initiate treatment with Hydrocodone Bitartrate and Acetaminophen Tablets with 1 tablet every 4 to 6 hours as needed for pain, at the lowest dose necessary to achieve adequate analgesia. Titrate the dose based upon the individual patient’s response to their initial dose of Hydrocodone Bitartrate and Acetaminophen Tablets. The total daily dosage should not exceed 6 tablets. Conversion from Other Opioids to Hydrocodone Bitartrate and Acetaminophen Tablets There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dosage of Hydrocodone Bitartrate and Acetaminophen Tablets. It is safer to underestimate a patient’s 24-hour Hydrocodone Bitartrate and Acetaminophen Tablets dosage than to overestimate the 24-hour Hydrocodone Bitartrate and Acetaminophen Tablets dosage and manage an adverse reaction due …
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Hydrocodone Bitartrate and Acetaminophen Tablets, USP are contraindicated in patients with: • Significant respiratory depression [see WARNINGS ] • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see WARNINGS ] • Known or suspected gastrointestinal obstruction, including paralytic ileus [see WARNINGS ] • Hypersensitivity to hydrocodone or acetaminophen (e.g., anaphylaxis) [see WARNINGS, ADVERSE REACTIONS]
Warnings
openFDA Drug LabelingWARNINGS Addiction, Abuse, and Misuse Hydrocodone bitartrate and acetaminophen tablets contain hydrocodone, a Schedule II controlled substance. As an opioid, hydrocodone bitartrate and acetaminophen tablets expose users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence]. Although the risk of addiction in any individual is unknown, it can occur in patient’s appropriately prescribed hydrocodone bitartrate and acetaminophen tablets. Addiction can occur at recommended dosages and if the drug is misused or abused. The risk of opioid-related overdose or overdose-related death is increased with higher opioid doses, and this risk persists over the course of therapy. In postmarketing studies, addiction, abuse, misuse, and fatal and non-fatal opioid overdose were observed in patients with long-term opioid use [Adverse Reactions; Postmarketing Experience]. Assess each patient’s risk for opioid addiction, abuse, or misuse prior to prescribing hydrocodone bitartrate and acetaminophen tablets, and reassess all patients receiving hydrocodone bitartrate and acetaminophen tablets for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as hydrocodone bitartrate and acetaminophen tablets, but use in such patients necessitates intensive counseling about the risks and proper use of hydrocodone bitartrate and acetaminophen tablets along with frequent reevaluation for signs of addiction, abuse, and misuse. Consider prescribing an opioid overdose reversal agent [see Warnings, Life-Threatening Respiratory Depression; Dosage and Administration, Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose]. Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing hydrocodone bitartrate and acetaminophen tablets. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on careful storage of the drug during the course of treatment and proper disposal of unused drug. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient’s clinical status [see Overdosage]. Carbon dioxide (CO 2 ) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of hydrocodone bitartrate and acetaminophen tablets, the risk is greatest during the initiation of therapy or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of hydrocodone bitartrate and acetaminophen tablets are essential [see Dosage and Administration]. Overestimating the hydrocodone bitartrate and acetaminophen tablets dosage when converting patients from another opioid product can result in a fatal overdose. Accidental ingestion of even one dose of hydrocodone bitartrate and acetaminophen tablets, especially by children, can result in respiratory depression and death due to an overdose of hydrocodone bitartrate and acetaminophen tablets. Educate patients and …
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following adverse reactions have been identified during post approval use of hydrocodone and acetaminophen tablets and Tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most frequently reported adverse reactions are light-headedness, dizziness, sedation, nausea and vomiting. Other adverse reactions include: Central Nervous System - Drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, psychological dependence, mood changes. Gastrointestinal System- Constipation. Genitourinary System- Ureteral spasm, spasm of vesical sphincters, and urinary retention. Special Senses- Cases of Hearing impairment or permanent loss have been reported predominantly in patients with chronic overdose. Dermatological- Skin rash, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, allergic reactions Hematological - Thrombocytopenia, agranulocytosis. Serotonin syndrome : Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs. • Adrenal insufficiency : Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. • Anaphylaxis : Anaphylaxis has been reported with ingredients contained in Hydrocodone Bitartrate and Acetaminophen Tablets. • Androgen deficiency : Cases of androgen deficiency have occurred with chronic use of opioids [see CLINICAL PHARMACOLOGY ]. DRUG ABUSE AND DEPENDENCE Controlled Substance Hydrocodone Bitartrate and Acetaminophen Tablets, USP contains hydrocodone, a Schedule II controlled substance. Abuse Hydrocodone Bitartrate and Acetaminophen Tablets, USP contains hydrocodone, a substance with a high potential for abuse similar to other opioids including. Hydrocodone Bitartrate and Acetaminophen Tablets, USP can be abused and is subject to misuse, addiction, and criminal diversion [see WARNINGS ]. All patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use. Prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and includes a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal. “Drug seeking” behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating healthcare provider(s). “Doctor shopping” (visiting multiple prescribers to obtain additional prescriptions) is common among drug abusers and people suffering from untreated addiction. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control. Abuse and addiction are separate and distinct from physical dependence and tolerance. Healthcare providers should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction. Hydrocodone Bitartrate and Acetaminophen Tablets, USP, like other opioids, can be diverted for non-medical use into illicit c …
Drug Interactions
openFDA Drug LabelingDRUG INTERACTIONS Inhibitors of CYP3A4 and CYP2D6 The concomitant use of hydrocodone bitartrate and acetaminophen tablets and CYP3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), and protease inhibitors (e.g., ritonavir), can increase the plasma concentration of the hydrocodone from hydrocodone bitartrate and acetaminophen tablets, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of hydrocodone bitartrate and acetaminophen tablets and both CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of hydrocodone bitartrate and acetaminophen tablets is achieved [see Warnings]. After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the hydrocodone plasma concentration will decrease [see Clinical Pharmacology], resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to hydrocodone bitartrate and acetaminophen tablets. If concomitant use is necessary, consider dosage reduction of hydrocodone bitartrate and acetaminophen tablets until stable drug effects are achieved. Evaluate patients at frequent intervals for respiratory depression and sedation. If a CYP3A4 inhibitor is discontinued, consider increasing the hydrocodone bitartrate and acetaminophen tablets dosage until stable drug effects are achieved. Evaluate for signs of opioid withdrawal. Inducers of CYP3A4 The concomitant use of hydrocodone bitartrate and acetaminophen tablets and CYP3A4 inducers, such as rifampin, carbamazepine, and phenytoin, can decrease the plasma concentration of hydrocodone [see Clinical Pharmacology], resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to hydrocodone [see Warnings]. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the hydrocodone plasma concentration will increase [see Clinical Pharmacology], which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression. If concomitant use is necessary, consider increasing hydrocodone bitartrate and acetaminophen tablets dosage until stable drug effects are achieved. Evaluate the patient for signs and symptoms of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider hydrocodone bitartrate and acetaminophen tablets dosage reduction and evaluate patients at frequent intervals for signs of respiratory depression and sedation. Benzodiazepines and Other Central Nervous System (CNS) Depressants Due to additive pharmacologic effect, the concomitant use of benzodiazepines and other CNS depressants, such as benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids, other opioids, alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction, educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider prescribing an opioid overdose reversal agent [see Warnings]. Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatr …
Mechanism of Action
openFDA Drug LabelingMechanism of Action Hydrocodone is a full opioid agonist with relative selectivity for the mu-opioid (μ) receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of hydrocodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with hydrocodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions.
Description
openFDA Drug LabelingDESCRIPTION Hydrocodone bitartrate and acetaminophen is available in tablet form for oral administration. Hydrocodone bitartrate is an opioid analgesic and occurs as fine, white crystals or as a crystalline powder. It is affected by light. The chemical name is 4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5). It has the following structural formula: Acetaminophen, 4 ́-hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula: Each Hydrocodone Bitartrate and Acetaminophen Tablet, USP 5 mg/300 mg contains: Hydrocodone Bitartrate. . . . . . . . 5 mg Acetaminophen. . . . . . . . . . . . . .300 mg Each Hydrocodone Bitartrate and Acetaminophen Tablet, USP 7.5 mg/300 mg contains: Hydrocodone Bitartrate. . . . . . . . .7.5 mg Acetaminophen. . . . . . . . . . . . . . 300 mg Each Hydrocodone Bitartrate and Acetaminophen Tablet, USP 10 mg/300 mg contains: Hydrocodone Bitartrate. . . . . . . . 10 mg Acetaminophen. . . . . . . . . . . . . .300 mg Each Hydrocodone Bitartrate and Acetaminophen Tablet, USP 5 mg/325 mg contains: Hydrocodone Bitartrate. . . . . . . . 5 mg Acetaminophen. . . . . . . . . . . . . .325 mg Each Hydrocodone Bitartrate and Acetaminophen Tablet, USP 7.5 mg/325 mg contains: Hydrocodone Bitartrate. . . . . . . . .7.5 mg Acetaminophen. . . . . . . . . . . . . . 325 mg Each Hydrocodone Bitartrate and Acetaminophen Tablet, USP 10 mg/325 mg contains: Hydrocodone Bitartrate. . . . . . . . 10 mg Acetaminophen. . . . . . . . . . . . . .325 mg In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, crospovidone, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch, and stearic acid. Hydrocodone Bitartrate and Acetaminophen Tablets, USP 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg: This product complies with USP dissolution test 2. Hydrocodone Bitartrate and Acetaminophen Tablets, USP 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg: This product complies with USP dissolution test 1. hbt-chemical-structure apap-chemical-structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Following an acute overdosage, toxicity may result from hydrocodone or acetaminophen. Clinical Presentation Acute overdose with hydrocodone bitartrate and acetaminophen tablets can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations. Acetaminophen Dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect of acetaminophen overdosage. Renal tubular necrosis, hypoglycemic coma and coagulation defects may also occur. Early symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion. Treatment of Overdose Hydrocodone In case of overdose, priorities are the reestablishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support techniques. The opioid antagonists, naloxone or nalmefene, are specific antidotes to respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to hydrocodone bitartrate and acetaminophen tablets overdose, administer an opioid antagonist. Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to hydrocodone bitartrate and acetaminophen tablets overdose. Because the duration of opioid reversal is expected to be less than the duration of action of hydrocodone bitartrate and acetaminophen tablets in hydrocodone bitartrate and acetaminophen tablets, carefully monitor the patient until spontaneous respiration is reliably re-established. If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product’s prescribing information. In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be begun with care and by titration with smaller than usual doses of the antagonist. Acetaminophen Gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation. Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading. To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving liver injury is suspected. Intravenous NAC may be administered when circumstances preclude oral administration. Vigorous supportive therapy is required in severe intoxication. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of intoxication.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Each tablet contains 5 mg of hydrocodone bitartrate and 325 mg of acetaminophen. They are available as white capsule-shaped tablets, bisected on one side and debossed on the other side with G 035. NDC 76420-875-01 Bottles of 1 (repackaged from NDC 27808-035-XX) NDC 76420-875-03 Bottles of 3 (repackaged from NDC 27808-035-XX) NDC 76420-875-07 Bottles of 7 (repackaged from NDC 27808-035-XX) NDC 76420-875-14 Bottles of 14 (repackaged from NDC 27808-035-XX) NDC 76420-875-20 Bottles of 20 (repackaged from NDC 27808-035-XX) NDC 76420-875-30 Bottles of 30 (repackaged from NDC 27808-035-XX) NDC 76420-875-60 Bottles of 60 (repackaged from NDC 27808-035-XX) NDC 76420-875-90 Bottles of 90 (repackaged from NDC 27808-035-XX) NDC 76420-875-10 Bottles of 100 (relabeled/repackaged from NDC 27808-035-01) NDC 76420-875-05 Bottles of 500 (relabeled/repackaged from NDC 27808-035-02) NDC 76420-875-00 Bottles of 1000 (relabeled/repackaged from NDC 27808-035-03) Each tablet contains 7.5 mg of hydrocodone bitartrate and 325 mg of acetaminophen. They are available as white capsule-shaped tablets, bisected on one side and debossed on the other side with G 036. NDC 76420-876-01 Bottles of 1 (repackaged from NDC 27808-036-XX) NDC 76420-876-03 Bottles of 3 (repackaged from NDC 27808-036-XX) NDC 76420-876-07 Bottles of 7 (repackaged from NDC 27808-036-XX) NDC 76420-876-14 Bottles of 14 (repackaged from NDC 27808-036-XX) NDC 76420-876-20 Bottles of 20 (repackaged from NDC 27808-036-XX) NDC 76420-876-30 Bottles of 30 (repackaged from NDC 27808-036-XX) NDC 76420-876-60 Bottles of 60 (repackaged from NDC 27808-036-XX) NDC 76420-876-90 Bottles of 90 (repackaged from NDC 27808-036-XX) NDC 76420-876-10 Bottles of 100 (relabeled/repackaged from NDC 27808-036-01) NDC 76420-876-05 Bottles of 500 (relabeled/repackaged from NDC 27808-036-02) NDC 76420-876-00 Bottles of 1000 (relabeled/repackaged from NDC 27808-036-03) Each tablet contains 10 mg of hydrocodone bitartrate and 325 mg of acetaminophen. They are available as white capsule-shaped tablets, bisected on one side and debossed on the other side with G 037. NDC 76420-877-01 Bottles of 1 (repackaged from NDC 27808-037-XX) NDC 76420-877-03 Bottles of 3 (repackaged from NDC 27808-037-XX) NDC 76420-877-07 Bottles of 7 (repackaged from NDC 27808-037-XX) NDC 76420-877-14 Bottles of 14 (repackaged from NDC 27808-037-XX) NDC 76420-877-20 Bottles of 20 (repackaged from NDC 27808-037-XX) NDC 76420-877-30 Bottles of 30 (repackaged from NDC 27808-037-XX) NDC 76420-877-60 Bottles of 60 (repackaged from NDC 27808-037-XX) NDC 76420-877-90 Bottles of 90 (repackaged from NDC 27808-037-XX) NDC 76420-877-10 Bottles of 100 (relabeled/repackaged from NDC 27808-037-01) NDC 76420-877-05 Bottles of 500 (relabeled/repackaged from NDC 27808-037-02) NDC 76420-877-00 Bottles of 1000 (relabeled/repackaged from NDC 27808-037-03) Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Store Hydrocodone Bitartrate and Acetaminophen Tablets securely and dispose of properly [see PRECAUTIONS / Information for Patients ]. PHARMACIST: Dispense in a tight, light-resistant container as defined in the USP with a child-resistant closure. Contains a Schedule II controlled drug substance. Relabeled and Repackaged by: Enovachem PHARMACEUTICALS Torrance, CA 90501
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: ACETAMINOPHEN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class II | December 15, 2021 | Ascent Pharmaceuticals, Inc. | Product Mix-up | Terminated |
| Class III | June 6, 2018 | LUPIN SOMERSET | Labeling: Missing Label | Terminated |
| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-1778-0 | 50090-1778 | A-S Medication Solutions | 20 TABLET in 1 BOTTLE (50090-1778-0) | April 14, 2015 |
| 50090-1778-7 | 50090-1778 | A-S Medication Solutions | 12 TABLET in 1 BOTTLE (50090-1778-7) | January 29, 2019 |
| 60687-396-01 | 60687-396 | American Health Packaging | 100 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-396-01) / 1 TABLET in 1 BLISTER PACK (60687-396-11) | June 27, 2023 |
| 60687-407-01 | 60687-407 | American Health Packaging | 100 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-407-01) / 1 TABLET in 1 BLISTER PACK (60687-407-11) | April 15, 2019 |
| 60687-418-01 | 60687-418 | American Health Packaging | 100 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-418-01) / 1 TABLET in 1 BLISTER PACK (60687-418-11) | April 15, 2019 |
| 65162-115-03 | 65162-115 | Amneal Pharmaceuticals LLC | 30 TABLET in 1 BOTTLE (65162-115-03) | June 30, 2016 |
| 65162-115-10 | 65162-115 | Amneal Pharmaceuticals LLC | 100 TABLET in 1 BOTTLE (65162-115-10) | June 30, 2016 |
| 65162-115-11 | 65162-115 | Amneal Pharmaceuticals LLC | 1000 TABLET in 1 BOTTLE (65162-115-11) | June 30, 2016 |
| 65162-115-50 | 65162-115 | Amneal Pharmaceuticals LLC | 500 TABLET in 1 BOTTLE (65162-115-50) | June 30, 2016 |
| 53746-109-01 | 53746-109 | Amneal Pharmaceuticals of New York LLC | 100 TABLET in 1 BOTTLE (53746-109-01) | January 18, 2010 |
| 53746-109-05 | 53746-109 | Amneal Pharmaceuticals of New York LLC | 500 TABLET in 1 BOTTLE (53746-109-05) | January 18, 2010 |
| 53746-109-10 | 53746-109 | Amneal Pharmaceuticals of New York LLC | 1000 TABLET in 1 BOTTLE (53746-109-10) | January 18, 2010 |
| 53746-110-01 | 53746-110 | Amneal Pharmaceuticals of New York LLC | 100 TABLET in 1 BOTTLE (53746-110-01) | February 18, 2010 |
| 53746-110-05 | 53746-110 | Amneal Pharmaceuticals of New York LLC | 500 TABLET in 1 BOTTLE (53746-110-05) | February 18, 2010 |
| 53746-110-10 | 53746-110 | Amneal Pharmaceuticals of New York LLC | 1000 TABLET in 1 BOTTLE (53746-110-10) | February 18, 2010 |
| 76420-133-01 | 76420-133 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE (76420-133-01) | November 10, 2025 |
| 76420-133-05 | 76420-133 | Asclemed USA, Inc. | 500 TABLET in 1 BOTTLE (76420-133-05) | November 10, 2025 |
| 76420-133-30 | 76420-133 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE (76420-133-30) | December 16, 2020 |
| 76420-133-60 | 76420-133 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE (76420-133-60) | November 10, 2025 |
| 76420-133-90 | 76420-133 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE (76420-133-90) | November 10, 2025 |
| 76420-215-01 | 76420-215 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE (76420-215-01) | May 10, 2022 |
| 76420-215-30 | 76420-215 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE (76420-215-30) | May 10, 2022 |
| 76420-215-60 | 76420-215 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE (76420-215-60) | May 10, 2022 |
| 76420-215-90 | 76420-215 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE (76420-215-90) | May 10, 2022 |
| 76420-257-30 | 76420-257 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE (76420-257-30) | July 20, 2022 |
| 76420-257-60 | 76420-257 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE (76420-257-60) | July 20, 2022 |
| 76420-257-90 | 76420-257 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE (76420-257-90) | July 20, 2022 |
| 76420-875-00 | 76420-875 | Asclemed USA, Inc. | 1000 TABLET in 1 BOTTLE, PLASTIC (76420-875-00) | November 12, 2024 |
| 76420-875-01 | 76420-875 | Asclemed USA, Inc. | 1 TABLET in 1 BOTTLE, PLASTIC (76420-875-01) | November 12, 2024 |
| 76420-875-03 | 76420-875 | Asclemed USA, Inc. | 3 TABLET in 1 BOTTLE, PLASTIC (76420-875-03) | November 12, 2024 |
| 76420-875-05 | 76420-875 | Asclemed USA, Inc. | 500 TABLET in 1 BOTTLE, PLASTIC (76420-875-05) | November 12, 2024 |
| 76420-875-07 | 76420-875 | Asclemed USA, Inc. | 7 TABLET in 1 BOTTLE, PLASTIC (76420-875-07) | November 12, 2024 |
| 76420-875-10 | 76420-875 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE, PLASTIC (76420-875-10) | November 12, 2024 |
| 76420-875-14 | 76420-875 | Asclemed USA, Inc. | 14 TABLET in 1 BOTTLE, PLASTIC (76420-875-14) | November 12, 2024 |
| 76420-875-20 | 76420-875 | Asclemed USA, Inc. | 20 TABLET in 1 BOTTLE, PLASTIC (76420-875-20) | November 12, 2024 |
| 76420-875-30 | 76420-875 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE, PLASTIC (76420-875-30) | November 12, 2024 |
| 76420-875-60 | 76420-875 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE, PLASTIC (76420-875-60) | November 12, 2024 |
| 76420-875-90 | 76420-875 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE, PLASTIC (76420-875-90) | November 12, 2024 |
| 76420-876-00 | 76420-876 | Asclemed USA, Inc. | 1000 TABLET in 1 BOTTLE, PLASTIC (76420-876-00) | November 12, 2024 |
| 76420-876-01 | 76420-876 | Asclemed USA, Inc. | 1 TABLET in 1 BOTTLE, PLASTIC (76420-876-01) | November 12, 2024 |
| 76420-876-03 | 76420-876 | Asclemed USA, Inc. | 3 TABLET in 1 BOTTLE, PLASTIC (76420-876-03) | November 12, 2024 |
| 76420-876-05 | 76420-876 | Asclemed USA, Inc. | 500 TABLET in 1 BOTTLE, PLASTIC (76420-876-05) | November 12, 2024 |
| 76420-876-07 | 76420-876 | Asclemed USA, Inc. | 7 TABLET in 1 BOTTLE, PLASTIC (76420-876-07) | November 12, 2024 |
| 76420-876-10 | 76420-876 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE, PLASTIC (76420-876-10) | November 12, 2024 |
| 76420-876-14 | 76420-876 | Asclemed USA, Inc. | 14 TABLET in 1 BOTTLE, PLASTIC (76420-876-14) | November 12, 2024 |
| 76420-876-20 | 76420-876 | Asclemed USA, Inc. | 20 TABLET in 1 BOTTLE, PLASTIC (76420-876-20) | November 12, 2024 |
| 76420-876-30 | 76420-876 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE, PLASTIC (76420-876-30) | November 12, 2024 |
| 76420-876-60 | 76420-876 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE, PLASTIC (76420-876-60) | November 12, 2024 |
| 76420-876-90 | 76420-876 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE, PLASTIC (76420-876-90) | November 12, 2024 |
| 76420-877-00 | 76420-877 | Asclemed USA, Inc. | 1000 TABLET in 1 BOTTLE, PLASTIC (76420-877-00) | November 12, 2024 |
| 76420-877-01 | 76420-877 | Asclemed USA, Inc. | 1 TABLET in 1 BOTTLE, PLASTIC (76420-877-01) | November 12, 2024 |
| 76420-877-03 | 76420-877 | Asclemed USA, Inc. | 3 TABLET in 1 BOTTLE, PLASTIC (76420-877-03) | November 12, 2024 |
| 76420-877-05 | 76420-877 | Asclemed USA, Inc. | 500 TABLET in 1 BOTTLE, PLASTIC (76420-877-05) | November 12, 2024 |
| 76420-877-07 | 76420-877 | Asclemed USA, Inc. | 7 TABLET in 1 BOTTLE, PLASTIC (76420-877-07) | November 12, 2024 |
| 76420-877-10 | 76420-877 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE, PLASTIC (76420-877-10) | November 12, 2024 |
| 76420-877-14 | 76420-877 | Asclemed USA, Inc. | 14 TABLET in 1 BOTTLE, PLASTIC (76420-877-14) | November 12, 2024 |
| 76420-877-20 | 76420-877 | Asclemed USA, Inc. | 20 TABLET in 1 BOTTLE, PLASTIC (76420-877-20) | November 12, 2024 |
| 76420-877-30 | 76420-877 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE, PLASTIC (76420-877-30) | November 12, 2024 |
| 76420-877-60 | 76420-877 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE, PLASTIC (76420-877-60) | November 12, 2024 |
| 76420-877-90 | 76420-877 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE, PLASTIC (76420-877-90) | November 12, 2024 |
| 87063-049-01 | 87063-049 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE (87063-049-01) | November 24, 2025 |
| 87063-049-05 | 87063-049 | Asclemed USA, Inc. | 5 TABLET in 1 BOTTLE (87063-049-05) | November 24, 2025 |
| 87063-049-07 | 87063-049 | Asclemed USA, Inc. | 7 TABLET in 1 BOTTLE (87063-049-07) | November 24, 2025 |
| 87063-049-10 | 87063-049 | Asclemed USA, Inc. | 10 TABLET in 1 BOTTLE (87063-049-10) | November 24, 2025 |
| 87063-049-14 | 87063-049 | Asclemed USA, Inc. | 14 TABLET in 1 BOTTLE (87063-049-14) | November 24, 2025 |
| 87063-049-20 | 87063-049 | Asclemed USA, Inc. | 20 TABLET in 1 BOTTLE (87063-049-20) | November 24, 2025 |
| 87063-049-30 | 87063-049 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE (87063-049-30) | November 24, 2025 |
| 87063-049-60 | 87063-049 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE (87063-049-60) | November 24, 2025 |
| 87063-049-90 | 87063-049 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE (87063-049-90) | November 24, 2025 |
| 87063-050-01 | 87063-050 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE (87063-050-01) | November 24, 2025 |
| 87063-050-05 | 87063-050 | Asclemed USA, Inc. | 5 TABLET in 1 BOTTLE (87063-050-05) | November 24, 2025 |
| 87063-050-07 | 87063-050 | Asclemed USA, Inc. | 7 TABLET in 1 BOTTLE (87063-050-07) | November 24, 2025 |
| 87063-050-10 | 87063-050 | Asclemed USA, Inc. | 10 TABLET in 1 BOTTLE (87063-050-10) | November 24, 2025 |
| 87063-050-14 | 87063-050 | Asclemed USA, Inc. | 14 TABLET in 1 BOTTLE (87063-050-14) | November 24, 2025 |
| 87063-050-20 | 87063-050 | Asclemed USA, Inc. | 20 TABLET in 1 BOTTLE (87063-050-20) | November 24, 2025 |
| 87063-050-30 | 87063-050 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE (87063-050-30) | November 24, 2025 |
| 87063-050-60 | 87063-050 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE (87063-050-60) | November 24, 2025 |
| 87063-050-90 | 87063-050 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE (87063-050-90) | November 24, 2025 |
| 87063-051-01 | 87063-051 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE (87063-051-01) | November 24, 2025 |
| 87063-051-05 | 87063-051 | Asclemed USA, Inc. | 5 TABLET in 1 BOTTLE (87063-051-05) | November 24, 2025 |
| 87063-051-07 | 87063-051 | Asclemed USA, Inc. | 7 TABLET in 1 BOTTLE (87063-051-07) | November 24, 2025 |
| 87063-051-10 | 87063-051 | Asclemed USA, Inc. | 10 TABLET in 1 BOTTLE (87063-051-10) | November 24, 2025 |
| 87063-051-14 | 87063-051 | Asclemed USA, Inc. | 14 TABLET in 1 BOTTLE (87063-051-14) | November 24, 2025 |
| 87063-051-20 | 87063-051 | Asclemed USA, Inc. | 20 TABLET in 1 BOTTLE (87063-051-20) | November 24, 2025 |
| 87063-051-30 | 87063-051 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE (87063-051-30) | November 24, 2025 |
| 87063-051-60 | 87063-051 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE (87063-051-60) | November 24, 2025 |
| 87063-051-90 | 87063-051 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE (87063-051-90) | November 24, 2025 |
| 13107-019-01 | 13107-019 | Aurolife Pharma, LLC | 100 TABLET in 1 BOTTLE (13107-019-01) | April 11, 2012 |
| 13107-019-05 | 13107-019 | Aurolife Pharma, LLC | 500 TABLET in 1 BOTTLE (13107-019-05) | April 11, 2012 |
| 13107-019-30 | 13107-019 | Aurolife Pharma, LLC | 30 TABLET in 1 BOTTLE (13107-019-30) | April 11, 2012 |
| 13107-019-99 | 13107-019 | Aurolife Pharma, LLC | 1000 TABLET in 1 BOTTLE (13107-019-99) | April 11, 2012 |
| 13107-020-01 | 13107-020 | Aurolife Pharma, LLC | 100 TABLET in 1 BOTTLE (13107-020-01) | April 11, 2012 |
| 13107-020-05 | 13107-020 | Aurolife Pharma, LLC | 500 TABLET in 1 BOTTLE (13107-020-05) | April 11, 2012 |
| 13107-020-30 | 13107-020 | Aurolife Pharma, LLC | 30 TABLET in 1 BOTTLE (13107-020-30) | April 11, 2012 |
| 13107-020-99 | 13107-020 | Aurolife Pharma, LLC | 1000 TABLET in 1 BOTTLE (13107-020-99) | April 11, 2012 |
| 13107-021-01 | 13107-021 | Aurolife Pharma, LLC | 100 TABLET in 1 BOTTLE (13107-021-01) | April 11, 2012 |
| 13107-021-05 | 13107-021 | Aurolife Pharma, LLC | 500 TABLET in 1 BOTTLE (13107-021-05) | April 11, 2012 |
| 13107-021-30 | 13107-021 | Aurolife Pharma, LLC | 30 TABLET in 1 BOTTLE (13107-021-30) | April 11, 2012 |
| 13107-021-99 | 13107-021 | Aurolife Pharma, LLC | 1000 TABLET in 1 BOTTLE (13107-021-99) | April 11, 2012 |
| 13107-211-01 | 13107-211 | Aurolife Pharma, LLC | 100 TABLET in 1 BOTTLE (13107-211-01) | May 6, 2015 |
| 13107-211-05 | 13107-211 | Aurolife Pharma, LLC | 500 TABLET in 1 BOTTLE (13107-211-05) | May 6, 2015 |
| 13107-211-30 | 13107-211 | Aurolife Pharma, LLC | 30 TABLET in 1 BOTTLE (13107-211-30) | May 6, 2015 |
| 13107-211-99 | 13107-211 | Aurolife Pharma, LLC | 1000 TABLET in 1 BOTTLE (13107-211-99) | May 6, 2015 |
| 13107-212-01 | 13107-212 | Aurolife Pharma, LLC | 100 TABLET in 1 BOTTLE (13107-212-01) | May 6, 2015 |
| 13107-212-05 | 13107-212 | Aurolife Pharma, LLC | 500 TABLET in 1 BOTTLE (13107-212-05) | May 6, 2015 |
| 13107-212-30 | 13107-212 | Aurolife Pharma, LLC | 30 TABLET in 1 BOTTLE (13107-212-30) | May 6, 2015 |
| 13107-212-99 | 13107-212 | Aurolife Pharma, LLC | 1000 TABLET in 1 BOTTLE (13107-212-99) | May 6, 2015 |
| 13107-213-01 | 13107-213 | Aurolife Pharma, LLC | 100 TABLET in 1 BOTTLE (13107-213-01) | May 6, 2015 |
| 13107-213-05 | 13107-213 | Aurolife Pharma, LLC | 500 TABLET in 1 BOTTLE (13107-213-05) | May 6, 2015 |
| 13107-213-30 | 13107-213 | Aurolife Pharma, LLC | 30 TABLET in 1 BOTTLE (13107-213-30) | May 6, 2015 |
| 13107-213-99 | 13107-213 | Aurolife Pharma, LLC | 1000 TABLET in 1 BOTTLE (13107-213-99) | May 6, 2015 |
| 50268-400-15 | 50268-400 | AvPAK | 50 BLISTER PACK in 1 BOX (50268-400-15) / 1 TABLET in 1 BLISTER PACK (50268-400-11) | October 28, 2016 |
| 50268-401-15 | 50268-401 | AvPAK | 50 BLISTER PACK in 1 BOX, UNIT-DOSE (50268-401-15) / 1 TABLET in 1 BLISTER PACK (50268-401-11) | September 15, 2014 |
| 50268-402-15 | 50268-402 | AvPAK | 50 BLISTER PACK in 1 BOX, UNIT-DOSE (50268-402-15) / 1 TABLET in 1 BLISTER PACK (50268-402-11) | September 15, 2014 |
| 63629-1177-1 | 63629-1177 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (63629-1177-1) | June 17, 2019 |
| 63629-1179-1 | 63629-1179 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE (63629-1179-1) | September 1, 2020 |
| 63629-1180-1 | 63629-1180 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (63629-1180-1) | November 9, 2022 |
| 63629-1181-1 | 63629-1181 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE (63629-1181-1) | September 1, 2020 |
| 63629-1183-1 | 63629-1183 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (63629-1183-1) | November 9, 2022 |
| 63629-1184-1 | 63629-1184 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE (63629-1184-1) | September 1, 2020 |
| 63629-1938-1 | 63629-1938 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (63629-1938-1) | July 13, 2018 |
| 63629-1939-1 | 63629-1939 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (63629-1939-1) | July 13, 2018 |
| 63629-1940-1 | 63629-1940 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE (63629-1940-1) | July 13, 2018 |
| 63629-2292-1 | 63629-2292 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (63629-2292-1) | October 6, 2014 |
| 63629-2293-1 | 63629-2293 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE, PLASTIC (63629-2293-1) | October 6, 2014 |
| 63629-2294-1 | 63629-2294 | Bryant Ranch Prepack | 1000 TABLET in 1 BOTTLE, PLASTIC (63629-2294-1) | October 6, 2014 |
| 63629-2295-1 | 63629-2295 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (63629-2295-1) | October 6, 2014 |
| 63629-2296-1 | 63629-2296 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE, PLASTIC (63629-2296-1) | October 6, 2014 |
| 63629-2297-1 | 63629-2297 | Bryant Ranch Prepack | 1000 TABLET in 1 BOTTLE, PLASTIC (63629-2297-1) | October 6, 2014 |
| 63629-2298-1 | 63629-2298 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (63629-2298-1) | October 6, 2014 |
| 63629-2299-1 | 63629-2299 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE, PLASTIC (63629-2299-1) | October 6, 2014 |
| 63629-2300-1 | 63629-2300 | Bryant Ranch Prepack | 1000 TABLET in 1 BOTTLE, PLASTIC (63629-2300-1) | October 6, 2014 |
| 63629-2308-1 | 63629-2308 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (63629-2308-1) | April 7, 2016 |
| 63629-2309-1 | 63629-2309 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (63629-2309-1) | April 7, 2016 |
| 63629-2310-1 | 63629-2310 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (63629-2310-1) | April 7, 2016 |
| 63629-2468-1 | 63629-2468 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE (63629-2468-1) | April 12, 2016 |
| 63629-2469-1 | 63629-2469 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (63629-2469-1) | April 12, 2016 |
| 63629-2470-1 | 63629-2470 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE (63629-2470-1) | April 12, 2016 |
| 63629-2471-1 | 63629-2471 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (63629-2471-1) | April 12, 2016 |
| 63629-5422-0 | 63629-5422 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (63629-5422-0) | July 25, 2017 |
| 63629-5422-1 | 63629-5422 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (63629-5422-1) | October 6, 2014 |
| 63629-5422-2 | 63629-5422 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (63629-5422-2) | October 14, 2014 |
| 63629-5422-3 | 63629-5422 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (63629-5422-3) | October 6, 2014 |
| 63629-5422-4 | 63629-5422 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (63629-5422-4) | October 6, 2014 |
| 63629-5422-5 | 63629-5422 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (63629-5422-5) | October 6, 2014 |
| 63629-5422-6 | 63629-5422 | Bryant Ranch Prepack | 50 TABLET in 1 BOTTLE (63629-5422-6) | December 22, 2019 |
| 63629-5422-7 | 63629-5422 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (63629-5422-7) | October 23, 2014 |
| 63629-5422-8 | 63629-5422 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE (63629-5422-8) | November 3, 2014 |
| 63629-5422-9 | 63629-5422 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE (63629-5422-9) | December 1, 2014 |
| 63629-8499-1 | 63629-8499 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (63629-8499-1) | April 12, 2016 |
| 63629-8885-1 | 63629-8885 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (63629-8885-1) | October 7, 2021 |
| 63629-8885-2 | 63629-8885 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (63629-8885-2) | October 7, 2021 |
| 63629-8885-3 | 63629-8885 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (63629-8885-3) | October 26, 2021 |
| 63629-8885-4 | 63629-8885 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (63629-8885-4) | September 5, 2024 |
| 63629-8885-5 | 63629-8885 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (63629-8885-5) | October 26, 2021 |
| 63629-8886-1 | 63629-8886 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (63629-8886-1) | October 6, 2021 |
| 63629-8886-2 | 63629-8886 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (63629-8886-2) | September 5, 2024 |
| 63629-8886-3 | 63629-8886 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (63629-8886-3) | October 6, 2021 |
| 63629-8886-4 | 63629-8886 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (63629-8886-4) | October 7, 2021 |
| 63629-8886-5 | 63629-8886 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (63629-8886-5) | October 13, 2021 |
| 71335-0108-0 | 71335-0108 | Bryant Ranch Prepack | 8 TABLET in 1 BOTTLE (71335-0108-0) | December 12, 2018 |
| 71335-0108-1 | 71335-0108 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-0108-1) | June 6, 2018 |
| 71335-0108-2 | 71335-0108 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE (71335-0108-2) | December 11, 2018 |
| 71335-0108-3 | 71335-0108 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-0108-3) | July 9, 2018 |
| 71335-0108-4 | 71335-0108 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-0108-4) | September 4, 2019 |
| 71335-0108-5 | 71335-0108 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-0108-5) | June 28, 2018 |
| 71335-0108-6 | 71335-0108 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-0108-6) | May 30, 2018 |
| 71335-0108-7 | 71335-0108 | Bryant Ranch Prepack | 56 TABLET in 1 BOTTLE (71335-0108-7) | October 8, 2024 |
| 71335-0108-8 | 71335-0108 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-0108-8) | May 22, 2018 |
| 71335-0108-9 | 71335-0108 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-0108-9) | May 31, 2018 |
| 71335-1271-0 | 71335-1271 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-1271-0) | July 23, 2019 |
| 71335-1271-1 | 71335-1271 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-1271-1) | November 6, 2019 |
| 71335-1271-2 | 71335-1271 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-1271-2) | July 23, 2019 |
| 71335-1271-3 | 71335-1271 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-1271-3) | August 9, 2024 |
| 71335-1271-4 | 71335-1271 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE (71335-1271-4) | August 9, 2024 |
| 71335-1271-5 | 71335-1271 | Bryant Ranch Prepack | 56 TABLET in 1 BOTTLE (71335-1271-5) | August 9, 2024 |
| 71335-1271-6 | 71335-1271 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-1271-6) | July 18, 2019 |
| 71335-1271-7 | 71335-1271 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE (71335-1271-7) | August 9, 2024 |
| 71335-1271-8 | 71335-1271 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-1271-8) | August 2, 2019 |
| 71335-1271-9 | 71335-1271 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-1271-9) | August 9, 2024 |
| 71335-1339-1 | 71335-1339 | Bryant Ranch Prepack | 21 TABLET in 1 BOTTLE (71335-1339-1) | September 11, 2019 |
| 71335-1339-2 | 71335-1339 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE (71335-1339-2) | November 25, 2019 |
| 71335-1339-3 | 71335-1339 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-1339-3) | October 21, 2019 |
| 71335-1417-0 | 71335-1417 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-1417-0) | January 10, 2020 |
| 71335-1417-1 | 71335-1417 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-1417-1) | January 14, 2020 |
| 71335-1417-2 | 71335-1417 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-1417-2) | October 2, 2020 |
| 71335-1417-3 | 71335-1417 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-1417-3) | December 6, 2019 |
| 71335-1417-4 | 71335-1417 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-1417-4) | January 21, 2020 |
| 71335-1417-5 | 71335-1417 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-1417-5) | May 15, 2020 |
| 71335-1417-6 | 71335-1417 | Bryant Ranch Prepack | 8 TABLET in 1 BOTTLE (71335-1417-6) | July 9, 2024 |
| 71335-1417-7 | 71335-1417 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-1417-7) | May 18, 2020 |
| 71335-1417-8 | 71335-1417 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE (71335-1417-8) | December 9, 2019 |
| 71335-1417-9 | 71335-1417 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE (71335-1417-9) | July 9, 2024 |
| 71335-1418-0 | 71335-1418 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-1418-0) | December 6, 2019 |
| 71335-1418-1 | 71335-1418 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-1418-1) | February 13, 2020 |
| 71335-1418-2 | 71335-1418 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-1418-2) | December 6, 2019 |
| 71335-1418-3 | 71335-1418 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-1418-3) | July 9, 2024 |
| 71335-1418-4 | 71335-1418 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE (71335-1418-4) | July 9, 2024 |
| 71335-1418-5 | 71335-1418 | Bryant Ranch Prepack | 56 TABLET in 1 BOTTLE (71335-1418-5) | July 9, 2024 |
| 71335-1418-6 | 71335-1418 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-1418-6) | December 9, 2019 |
| 71335-1418-7 | 71335-1418 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE (71335-1418-7) | July 9, 2024 |
| 71335-1418-8 | 71335-1418 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-1418-8) | January 6, 2020 |
| 71335-1418-9 | 71335-1418 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-1418-9) | July 9, 2024 |
| 71335-1419-0 | 71335-1419 | Bryant Ranch Prepack | 8 TABLET in 1 BOTTLE (71335-1419-0) | May 12, 2020 |
| 71335-1419-1 | 71335-1419 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-1419-1) | March 31, 2020 |
| 71335-1419-2 | 71335-1419 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE (71335-1419-2) | July 6, 2020 |
| 71335-1419-3 | 71335-1419 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-1419-3) | March 6, 2020 |
| 71335-1419-4 | 71335-1419 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-1419-4) | July 9, 2024 |
| 71335-1419-5 | 71335-1419 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-1419-5) | February 20, 2020 |
| 71335-1419-6 | 71335-1419 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-1419-6) | July 9, 2024 |
| 71335-1419-7 | 71335-1419 | Bryant Ranch Prepack | 56 TABLET in 1 BOTTLE (71335-1419-7) | July 9, 2024 |
| 71335-1419-8 | 71335-1419 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-1419-8) | December 13, 2019 |
| 71335-1419-9 | 71335-1419 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-1419-9) | March 11, 2020 |
| 71335-1444-1 | 71335-1444 | Bryant Ranch Prepack | 21 TABLET in 1 BOTTLE (71335-1444-1) | April 2, 2020 |
| 71335-1444-2 | 71335-1444 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE (71335-1444-2) | June 15, 2020 |
| 71335-1444-3 | 71335-1444 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-1444-3) | December 23, 2019 |
| 71335-1470-1 | 71335-1470 | Bryant Ranch Prepack | 21 TABLET in 1 BOTTLE (71335-1470-1) | January 14, 2020 |
| 71335-1470-2 | 71335-1470 | Bryant Ranch Prepack | 12 TABLET in 1 BOTTLE (71335-1470-2) | August 19, 2020 |
| 71335-1470-3 | 71335-1470 | Bryant Ranch Prepack | 18 TABLET in 1 BOTTLE (71335-1470-3) | August 12, 2024 |
| 71335-1557-1 | 71335-1557 | Bryant Ranch Prepack | 21 TABLET in 1 BOTTLE (71335-1557-1) | June 7, 2021 |
| 71335-1557-2 | 71335-1557 | Bryant Ranch Prepack | 36 TABLET in 1 BOTTLE (71335-1557-2) | April 2, 2020 |
| 71335-1557-3 | 71335-1557 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-1557-3) | May 13, 2026 |
| 71335-1811-1 | 71335-1811 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-1811-1) | August 12, 2024 |
| 71335-1811-2 | 71335-1811 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-1811-2) | August 12, 2024 |
| 71335-1811-3 | 71335-1811 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-1811-3) | August 12, 2024 |
| 71335-1811-4 | 71335-1811 | Bryant Ranch Prepack | 8 TABLET in 1 BOTTLE (71335-1811-4) | March 19, 2021 |
| 71335-1811-5 | 71335-1811 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-1811-5) | August 12, 2024 |
| 71335-1811-6 | 71335-1811 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-1811-6) | August 12, 2024 |
| 71335-1970-1 | 71335-1970 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-1970-1) | October 7, 2021 |
| 71335-1970-2 | 71335-1970 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE (71335-1970-2) | September 6, 2024 |
| 71335-1970-3 | 71335-1970 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-1970-3) | September 6, 2024 |
| 71335-1970-4 | 71335-1970 | Bryant Ranch Prepack | 56 TABLET in 1 BOTTLE (71335-1970-4) | September 6, 2024 |
| 71335-1970-5 | 71335-1970 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-1970-5) | October 7, 2021 |
| 71335-1970-6 | 71335-1970 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-1970-6) | October 26, 2021 |
| 71335-1970-7 | 71335-1970 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-1970-7) | October 26, 2021 |
| 71335-2103-1 | 71335-2103 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2103-1) | June 6, 2022 |
| 71335-2103-2 | 71335-2103 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2103-2) | June 6, 2022 |
| 71335-2103-3 | 71335-2103 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2103-3) | June 6, 2022 |
| 71335-2103-4 | 71335-2103 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-2103-4) | June 6, 2022 |
| 71335-2103-5 | 71335-2103 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-2103-5) | June 6, 2022 |
| 71335-2104-1 | 71335-2104 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2104-1) | June 6, 2022 |
| 71335-2104-2 | 71335-2104 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE (71335-2104-2) | June 6, 2022 |
| 71335-2104-3 | 71335-2104 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-2104-3) | June 6, 2022 |
| 71335-2104-4 | 71335-2104 | Bryant Ranch Prepack | 56 TABLET in 1 BOTTLE (71335-2104-4) | June 6, 2022 |
| 71335-2104-5 | 71335-2104 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2104-5) | June 6, 2022 |
| 71335-2104-6 | 71335-2104 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2104-6) | June 6, 2022 |
| 71335-2104-7 | 71335-2104 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-2104-7) | June 6, 2022 |
| 71335-2105-1 | 71335-2105 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2105-1) | June 6, 2022 |
| 71335-2105-2 | 71335-2105 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-2105-2) | June 6, 2022 |
| 71335-2105-3 | 71335-2105 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2105-3) | June 6, 2022 |
| 71335-2105-4 | 71335-2105 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2105-4) | June 6, 2022 |
| 71335-2105-5 | 71335-2105 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-2105-5) | June 6, 2022 |
| 71335-2112-1 | 71335-2112 | Bryant Ranch Prepack | 21 TABLET in 1 BOTTLE (71335-2112-1) | June 20, 2022 |
| 71335-2112-2 | 71335-2112 | Bryant Ranch Prepack | 36 TABLET in 1 BOTTLE (71335-2112-2) | June 20, 2022 |
| 71335-2112-3 | 71335-2112 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-2112-3) | June 20, 2022 |
| 71335-2115-0 | 71335-2115 | Bryant Ranch Prepack | 8 TABLET in 1 BOTTLE (71335-2115-0) | June 20, 2022 |
| 71335-2115-1 | 71335-2115 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-2115-1) | June 20, 2022 |
| 71335-2115-2 | 71335-2115 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE (71335-2115-2) | June 20, 2022 |
| 71335-2115-3 | 71335-2115 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-2115-3) | June 20, 2022 |
| 71335-2115-4 | 71335-2115 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-2115-4) | June 20, 2022 |
| 71335-2115-5 | 71335-2115 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2115-5) | June 20, 2022 |
| 71335-2115-6 | 71335-2115 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-2115-6) | June 20, 2022 |
| 71335-2115-7 | 71335-2115 | Bryant Ranch Prepack | 56 TABLET in 1 BOTTLE (71335-2115-7) | June 20, 2022 |
| 71335-2115-8 | 71335-2115 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2115-8) | June 20, 2022 |
| 71335-2115-9 | 71335-2115 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2115-9) | June 20, 2022 |
| 71335-2116-1 | 71335-2116 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2116-1) | September 6, 2024 |
| 71335-2116-2 | 71335-2116 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2116-2) | September 6, 2024 |
| 71335-2116-3 | 71335-2116 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2116-3) | September 6, 2024 |
| 71335-2116-4 | 71335-2116 | Bryant Ranch Prepack | 8 TABLET in 1 BOTTLE (71335-2116-4) | June 13, 2022 |
| 71335-2116-5 | 71335-2116 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-2116-5) | September 6, 2024 |
| 71335-2117-0 | 71335-2117 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-2117-0) | June 20, 2022 |
| 71335-2117-1 | 71335-2117 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2117-1) | June 20, 2022 |
| 71335-2117-2 | 71335-2117 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-2117-2) | June 20, 2022 |
| 71335-2117-3 | 71335-2117 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-2117-3) | June 20, 2022 |
| 71335-2117-4 | 71335-2117 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2117-4) | June 20, 2022 |
| 71335-2117-5 | 71335-2117 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2117-5) | June 20, 2022 |
| 71335-2117-6 | 71335-2117 | Bryant Ranch Prepack | 50 TABLET in 1 BOTTLE (71335-2117-6) | June 20, 2022 |
| 71335-2117-7 | 71335-2117 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-2117-7) | June 20, 2022 |
| 71335-2117-8 | 71335-2117 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE (71335-2117-8) | June 20, 2022 |
| 71335-2117-9 | 71335-2117 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE (71335-2117-9) | June 20, 2022 |
| 71335-2118-0 | 71335-2118 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-2118-0) | June 20, 2022 |
| 71335-2118-1 | 71335-2118 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-2118-1) | June 20, 2022 |
| 71335-2118-2 | 71335-2118 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2118-2) | June 20, 2022 |
| 71335-2118-3 | 71335-2118 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-2118-3) | June 20, 2022 |
| 71335-2118-4 | 71335-2118 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE (71335-2118-4) | June 20, 2022 |
| 71335-2118-5 | 71335-2118 | Bryant Ranch Prepack | 56 TABLET in 1 BOTTLE (71335-2118-5) | June 20, 2022 |
| 71335-2118-6 | 71335-2118 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2118-6) | June 20, 2022 |
| 71335-2118-7 | 71335-2118 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE (71335-2118-7) | June 20, 2022 |
| 71335-2118-8 | 71335-2118 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2118-8) | June 20, 2022 |
| 71335-2118-9 | 71335-2118 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-2118-9) | June 20, 2022 |
| 71335-2144-0 | 71335-2144 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-2144-0) | August 1, 2022 |
| 71335-2144-1 | 71335-2144 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2144-1) | September 6, 2024 |
| 71335-2144-2 | 71335-2144 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-2144-2) | September 6, 2024 |
| 71335-2144-3 | 71335-2144 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-2144-3) | August 1, 2022 |
| 71335-2144-4 | 71335-2144 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2144-4) | September 6, 2024 |
| 71335-2144-5 | 71335-2144 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2144-5) | September 6, 2024 |
| 71335-2144-6 | 71335-2144 | Bryant Ranch Prepack | 50 TABLET in 1 BOTTLE (71335-2144-6) | September 6, 2024 |
| 71335-2144-7 | 71335-2144 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-2144-7) | September 6, 2024 |
| 71335-2144-8 | 71335-2144 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE (71335-2144-8) | September 6, 2024 |
| 71335-2144-9 | 71335-2144 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE (71335-2144-9) | September 6, 2024 |
| 71335-2195-1 | 71335-2195 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2195-1) | December 1, 2022 |
| 71335-2195-2 | 71335-2195 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2195-2) | December 1, 2022 |
| 71335-2195-3 | 71335-2195 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2195-3) | December 1, 2022 |
| 71335-2195-4 | 71335-2195 | Bryant Ranch Prepack | 8 TABLET in 1 BOTTLE (71335-2195-4) | December 1, 2022 |
| 71335-2195-5 | 71335-2195 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-2195-5) | December 1, 2022 |
| 71335-2195-6 | 71335-2195 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-2195-6) | December 1, 2022 |
| 71335-2238-1 | 71335-2238 | Bryant Ranch Prepack | 21 TABLET in 1 BOTTLE, PLASTIC (71335-2238-1) | May 28, 2024 |
| 71335-2238-2 | 71335-2238 | Bryant Ranch Prepack | 36 TABLET in 1 BOTTLE, PLASTIC (71335-2238-2) | May 28, 2024 |
| 71335-2238-3 | 71335-2238 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE, PLASTIC (71335-2238-3) | May 28, 2024 |
| 71335-2585-1 | 71335-2585 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2585-1) | April 3, 2025 |
| 71335-2585-2 | 71335-2585 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2585-2) | April 3, 2025 |
| 71335-2585-3 | 71335-2585 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2585-3) | April 3, 2025 |
| 71335-2585-4 | 71335-2585 | Bryant Ranch Prepack | 8 TABLET in 1 BOTTLE (71335-2585-4) | April 3, 2025 |
| 71335-2585-5 | 71335-2585 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-2585-5) | April 3, 2025 |
| 71335-2585-6 | 71335-2585 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-2585-6) | April 3, 2025 |
| 71335-2740-1 | 71335-2740 | Bryant Ranch Prepack | 1000 TABLET in 1 BOTTLE (71335-2740-1) | July 29, 2025 |
| 71335-2969-1 | 71335-2969 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-2969-1) | October 23, 2025 |
| 71335-9602-1 | 71335-9602 | Bryant Ranch Prepack | 21 TABLET in 1 BOTTLE (71335-9602-1) | December 12, 2022 |
| 71335-9602-2 | 71335-9602 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE (71335-9602-2) | December 12, 2022 |
| 71335-9602-3 | 71335-9602 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-9602-3) | December 12, 2022 |
| 71335-9734-0 | 71335-9734 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE, PLASTIC (71335-9734-0) | June 8, 2023 |
| 71335-9734-1 | 71335-9734 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE, PLASTIC (71335-9734-1) | May 15, 2023 |
| 71335-9734-2 | 71335-9734 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE, PLASTIC (71335-9734-2) | May 30, 2023 |
| 71335-9734-3 | 71335-9734 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE, PLASTIC (71335-9734-3) | May 30, 2023 |
| 71335-9734-4 | 71335-9734 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE, PLASTIC (71335-9734-4) | June 2, 2023 |
| 71335-9734-5 | 71335-9734 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE, PLASTIC (71335-9734-5) | October 18, 2023 |
| 71335-9734-6 | 71335-9734 | Bryant Ranch Prepack | 50 TABLET in 1 BOTTLE, PLASTIC (71335-9734-6) | April 9, 2026 |
| 71335-9734-7 | 71335-9734 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE, PLASTIC (71335-9734-7) | October 17, 2023 |
| 71335-9734-8 | 71335-9734 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE, PLASTIC (71335-9734-8) | May 30, 2023 |
| 71335-9734-9 | 71335-9734 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE, PLASTIC (71335-9734-9) | April 9, 2026 |
| 71335-9735-0 | 71335-9735 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE, PLASTIC (71335-9735-0) | May 30, 2023 |
| 71335-9735-1 | 71335-9735 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE, PLASTIC (71335-9735-1) | May 30, 2023 |
| 71335-9735-2 | 71335-9735 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE, PLASTIC (71335-9735-2) | May 30, 2023 |
| 71335-9735-3 | 71335-9735 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE, PLASTIC (71335-9735-3) | April 9, 2026 |
| 71335-9735-4 | 71335-9735 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE, PLASTIC (71335-9735-4) | April 9, 2026 |
| 71335-9735-5 | 71335-9735 | Bryant Ranch Prepack | 56 TABLET in 1 BOTTLE, PLASTIC (71335-9735-5) | April 9, 2026 |
| 71335-9735-6 | 71335-9735 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE, PLASTIC (71335-9735-6) | May 8, 2023 |
| 71335-9735-7 | 71335-9735 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE, PLASTIC (71335-9735-7) | April 9, 2026 |
| 71335-9735-8 | 71335-9735 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE, PLASTIC (71335-9735-8) | July 5, 2023 |
| 71335-9735-9 | 71335-9735 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (71335-9735-9) | April 9, 2026 |
| 71335-9736-0 | 71335-9736 | Bryant Ranch Prepack | 8 TABLET in 1 BOTTLE, PLASTIC (71335-9736-0) | April 9, 2026 |
| 71335-9736-1 | 71335-9736 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE, PLASTIC (71335-9736-1) | November 28, 2023 |
| 71335-9736-2 | 71335-9736 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE, PLASTIC (71335-9736-2) | October 17, 2023 |
| 71335-9736-3 | 71335-9736 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE, PLASTIC (71335-9736-3) | June 28, 2023 |
| 71335-9736-4 | 71335-9736 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE, PLASTIC (71335-9736-4) | April 9, 2026 |
| 71335-9736-5 | 71335-9736 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE, PLASTIC (71335-9736-5) | September 6, 2023 |
| 71335-9736-6 | 71335-9736 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE, PLASTIC (71335-9736-6) | April 9, 2026 |
| 71335-9736-7 | 71335-9736 | Bryant Ranch Prepack | 56 TABLET in 1 BOTTLE, PLASTIC (71335-9736-7) | April 9, 2026 |
| 71335-9736-8 | 71335-9736 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE, PLASTIC (71335-9736-8) | December 5, 2023 |
| 71335-9736-9 | 71335-9736 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE, PLASTIC (71335-9736-9) | December 15, 2023 |
| 71335-9737-1 | 71335-9737 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE, PLASTIC (71335-9737-1) | April 9, 2026 |
| 71335-9737-2 | 71335-9737 | Bryant Ranch Prepack | 15 TABLET in 1 BOTTLE, PLASTIC (71335-9737-2) | April 9, 2026 |
| 71335-9737-3 | 71335-9737 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE, PLASTIC (71335-9737-3) | April 9, 2026 |
| 71335-9737-4 | 71335-9737 | Bryant Ranch Prepack | 56 TABLET in 1 BOTTLE, PLASTIC (71335-9737-4) | April 9, 2026 |
| 71335-9737-5 | 71335-9737 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE, PLASTIC (71335-9737-5) | June 14, 2023 |
| 71335-9737-6 | 71335-9737 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE, PLASTIC (71335-9737-6) | April 9, 2026 |
| 71335-9737-7 | 71335-9737 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE, PLASTIC (71335-9737-7) | April 9, 2026 |
| 72162-1279-0 | 72162-1279 | Bryant Ranch Prepack | 1000 TABLET in 1 BOTTLE, PLASTIC (72162-1279-0) | October 6, 2014 |
| 72162-1279-1 | 72162-1279 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (72162-1279-1) | October 6, 2014 |
| 72162-1279-5 | 72162-1279 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE, PLASTIC (72162-1279-5) | October 6, 2014 |
| 72162-1280-0 | 72162-1280 | Bryant Ranch Prepack | 1000 TABLET in 1 BOTTLE, PLASTIC (72162-1280-0) | October 6, 2014 |
| 72162-1280-1 | 72162-1280 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (72162-1280-1) | October 6, 2014 |
| 72162-1280-5 | 72162-1280 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE, PLASTIC (72162-1280-5) | October 6, 2014 |
| 72162-1280-6 | 72162-1280 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE, PLASTIC (72162-1280-6) | October 6, 2014 |
| 72162-1281-0 | 72162-1281 | Bryant Ranch Prepack | 1000 TABLET in 1 BOTTLE, PLASTIC (72162-1281-0) | October 6, 2014 |
| 72162-1281-1 | 72162-1281 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (72162-1281-1) | October 6, 2014 |
| 72162-1281-5 | 72162-1281 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE, PLASTIC (72162-1281-5) | October 6, 2014 |
| 72162-1287-1 | 72162-1287 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (72162-1287-1) | April 7, 2016 |
| 72162-1288-1 | 72162-1288 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (72162-1288-1) | April 7, 2016 |
| 72162-1289-1 | 72162-1289 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (72162-1289-1) | April 7, 2016 |
| 72162-1341-1 | 72162-1341 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (72162-1341-1) | April 12, 2016 |
| 72162-1341-5 | 72162-1341 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE (72162-1341-5) | April 12, 2016 |
| 72162-1342-1 | 72162-1342 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (72162-1342-1) | April 12, 2016 |
| 72162-1989-1 | 72162-1989 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (72162-1989-1) | July 13, 2018 |
| 72162-1990-5 | 72162-1990 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE (72162-1990-5) | July 13, 2018 |
| 72162-1991-1 | 72162-1991 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (72162-1991-1) | July 13, 2018 |
| 72162-1996-1 | 72162-1996 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (72162-1996-1) | June 17, 2019 |
| 72162-1996-5 | 72162-1996 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE (72162-1996-5) | June 17, 2019 |
| 72162-1997-1 | 72162-1997 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (72162-1997-1) | June 17, 2019 |
| 72162-1997-5 | 72162-1997 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE (72162-1997-5) | June 17, 2019 |
| 72162-1998-1 | 72162-1998 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (72162-1998-1) | June 17, 2019 |
| 72162-1998-5 | 72162-1998 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE (72162-1998-5) | June 17, 2019 |
| 72162-2271-1 | 72162-2271 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (72162-2271-1) | April 12, 2016 |
| 72162-2271-5 | 72162-2271 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE (72162-2271-5) | April 12, 2016 |
| 31722-940-01 | 31722-940 | Camber Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (31722-940-01) | August 22, 2025 |
| 31722-942-01 | 31722-942 | Camber Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (31722-942-01) | August 22, 2025 |
| 31722-942-05 | 31722-942 | Camber Pharmaceuticals, Inc. | 500 TABLET in 1 BOTTLE (31722-942-05) | August 22, 2025 |
| 31722-996-01 | 31722-996 | Camber Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (31722-996-01) | November 8, 2018 |
| 31722-996-05 | 31722-996 | Camber Pharmaceuticals, Inc. | 500 TABLET in 1 BOTTLE (31722-996-05) | November 8, 2018 |
| 31722-997-01 | 31722-997 | Camber Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (31722-997-01) | November 8, 2018 |
| 31722-997-05 | 31722-997 | Camber Pharmaceuticals, Inc. | 500 TABLET in 1 BOTTLE (31722-997-05) | November 8, 2018 |
| 27808-035-01 | 27808-035 | Cranbury Pharmaceuticals, LLC | 100 TABLET in 1 BOTTLE, PLASTIC (27808-035-01) | October 6, 2014 |
| 27808-035-02 | 27808-035 | Cranbury Pharmaceuticals, LLC | 500 TABLET in 1 BOTTLE, PLASTIC (27808-035-02) | October 6, 2014 |
| 27808-035-03 | 27808-035 | Cranbury Pharmaceuticals, LLC | 1000 TABLET in 1 BOTTLE, PLASTIC (27808-035-03) | October 6, 2014 |
| 27808-036-01 | 27808-036 | Cranbury Pharmaceuticals, LLC | 100 TABLET in 1 BOTTLE, PLASTIC (27808-036-01) | October 6, 2014 |
| 27808-036-02 | 27808-036 | Cranbury Pharmaceuticals, LLC | 500 TABLET in 1 BOTTLE, PLASTIC (27808-036-02) | October 6, 2014 |
| 27808-036-03 | 27808-036 | Cranbury Pharmaceuticals, LLC | 1000 TABLET in 1 BOTTLE, PLASTIC (27808-036-03) | October 6, 2014 |
| 27808-037-01 | 27808-037 | Cranbury Pharmaceuticals, LLC | 100 TABLET in 1 BOTTLE, PLASTIC (27808-037-01) | October 6, 2014 |
| 27808-037-02 | 27808-037 | Cranbury Pharmaceuticals, LLC | 500 TABLET in 1 BOTTLE, PLASTIC (27808-037-02) | October 6, 2014 |
| 27808-037-03 | 27808-037 | Cranbury Pharmaceuticals, LLC | 1000 TABLET in 1 BOTTLE, PLASTIC (27808-037-03) | October 6, 2014 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 13 sections on this page.